Company profile

Numab Therapeutics AG

Numab is a Swiss biotech company that innovates and develops antibody-based therapeutics. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane proteins. Numab’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.

Source: startup.ch

Highlights

Top 100 Swiss Startup Award 2021

Top 100 Swiss Startup Award 2014

Innosuisse Certificate

Top 100 Swiss Startup Award 2013

More news about Numab Therapeutics AG

14.02.2024 17:00

Numab Therapeutics extends partnership with Ono Pharmaceutical

Financing

Success

20.10.2023 11:46

Early-stage pharmaceutical companies make strides in cancer- and immunotherapy

Background

15.05.2023 14:00

Numab Therapeutics doses first patient with eczema

Success

04.04.2022 09:02

Numab signs a CHF 258 million deal with Ono Pharmaceuticles

Success

20.05.2021 09:25

Numab Therapeutics Completes CHF 100 Million Series C Financing

Financing

13.01.2021 17:04

Numab Therapeutics signs co-development partnership with Japanese Pharma

Financing

Success

05.10.2020 17:15

Startups win strong and well-connected board members

Background

24.08.2020 11:08

Numab Therapeutics advances to the clinical trials stage

Launch

09.07.2020 08:41

Boehringer Ingelheim to Develop Antibody Therapeutics with Numab

Expansion

Success

30.03.2020 11:20

Numab Therapeutics to receive additional CHF 260M from its Japanese partner

Financing

09.03.2020 13:29

Numab Therapeutics raises CHF 22M series B round

Financing

13.12.2019 11:24

A new partner and investor for Numab

Expansion

Financing

16.10.2019 09:42

Daniel Vasella joins biotech startup

Success

01.10.2019 09:38

Eisai teams up with Numab to generate cancer therapeutics

Success

03.05.2019 09:02

Numab signs licensing deal with Chinese biopharmaceutical company

Financing

Success

15.09.2017 13:44

Intarcia and Numab Reach Key Milestone

Success

16.06.2017 13:37

Numab achieves milestones and signs new partnerships

Success

29.03.2017 17:15

Profitable deal for Numab

Financing

Success

09.06.2015 17:23

Tillotts and Numab conclude license agreement

Success

20.03.2015 09:07

Intarcia and Numab to develop once-yearly therapies in diabetes, obesity and autoimmune indications

12.06.2014 10:37

Milestone payment for Numab

30.10.2013 07:34

Numab Reacquires Advanced Compound from Sucampo

31.07.2013 08:50

Robert Kamen Joins Numab’s Advisory Board

19.03.2013 11:03

Numab Earns Milestone Payment from Sucampo

07.12.2012 19:55

More start-ups than ever at the Swiss Venture Day

Support

23.11.2012 13:41

Eight promising start-ups present at the next Swiss Venture Day

20.06.2012 17:22

CTI Start-up Label for Numab, Qvanteq, SwissTV and Virometix

12.06.2012 14:45

Grow Wädenswil im Aufwärtstrend

Support

07.03.2012 11:16

CTI supports Numabs pipeline with CHF 895000

Founded
2011

Kanton
ZH

Homepage

Principal

Swiss Venture Capital Report

The new Swiss Venture Capital Report provides a review of the whole of 2023. In addition to investments, the report will once again include the results of a survey of Swiss investors, an overview of venture capital fundraising and a list of exits. You can download the Report in our asset section.